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Summary In a single centre, 52 newly diagnosed patients with acute myeloid leukaemia (AML) under the age
of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and
etoposide (Protocol BFI1), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered
remission using these drugs. An anthracycline was added for those patients not in remission. The overall
remission rate (CR) was 86.5% (45/52), with a minimum follow-up of 90 days. Patients are hospitalised for
relatively short periods, and consequently require less blood product and antibiotic support. Patients in
continuing first remission following, induction with Ara-C and etoposide are similar in number to those in
continuing first remission who initially received an anthracycline. This would imply that the efficiency of
Ara-C and etoposide in inducing long-term disease-free survival is comparable with anthracycline-containing
regimens. We conclude that high-dose Ara-C and etoposide used in the first induction cycle for treating AML
have good antileukaemic effect with acceptable toxicity.
Patients with AML with first remission can now expect a
cure rate of 45-60% following either ABMT or BMT (Hurd,
1987). These results, however, depend upon obtaining remis-
sion, higher CR rates rendering more patients eligible for a
bone marrow transplant procedure (Powles et al., 1980a).
Recent clinical trials using various combinations of drugs
including anthracyclines have not resulted in significantly
improved remission rates, and have usually involved pro-
tracted treatment (Mayer, 1987; Preisler et al., 1987a; Cassi-
leth et al., 1987; Capizzi et al., 1987; Rohatiner et al., 1988).
Treatment-related morbidity is thus increased, with the atten-
dant financial burdens of hospitalisation, together with con-
tinued requirement for blood product and antibiotic support.
Etoposide is effective in the treatment of acute leukaemia
(AL) (Gore et al., 1989; O'Dwyer et al., 1985), and pre-
clinical trials have shown it to be synergistic when used in
conjunction with Ara-C (Rivera et al., 1975). Several studies
have reported use of this in acute lymphoblastic leukaemia
(ALL), and as consolidation for AML prior to BMT (Morra
et al., 1984; Champlin et al., 1987). We have previously
shown its efficacy in achieving CR in patients with relapsed
and refactory AML (Gore et al., 1989), and it was therefore
decided to use this drug combination to treat de novo AML.
Use of an anthracycline was excluded in the first cycle of
induction chemotherapy, with the aim of reducing toxicity
and improving speed and frequency of achieving CR.
Patients and methods
Between September 1985 and February 1989, 52 newly diag-
nosed patients with AML were treated with high-dose Ara-C
and etoposide (Figure 1). Table I shows patient details.
Twenty-eight males were included (age 11-56 years; median
28), and 24 females (age 6-52 years; median 35). FAB
subtyping showed 25 (49%) to have a monocytic component
to their disease. Ara-C was infused intravenously (i.v.) at a
dose of 2 g m-2 over 3 h, twice daily for 5 consecutive days
(Gore et al., 1989). Etoposide 100 mg m 2 was given concur-
rently over 1 h for 5 days. The initial 29 patients received this
drug twice daily and the subsequent 23 patients once daily,
an unacceptably high incidence of gastrointestinal symptoms
having necessitated a dose reduction (Table IV).
Figure 1 Newly diagnosed AML: Induction protocol
Ara-C
etoposide
2gm-2 over 3 hours
100 mg m-2 over 1 hour
b.d. x 5 days
o.d./b.d. x 5 days
blast % in bone marrow aspirate
>10%
Ara-C 10mgkg' days 1,10
6TG 200mgm2 days 1,2,10,11
daunomytin 1.5 mg kg-1 days 2,11
adriamycin 1.5 mg kg- days 3,12
5-10%
Ara-C 60mgm2 s.c. b.d.
6TG 80mg p.o. b.d.
both drugs in three blocks o
5 days each at intervals
of 5 days
After achieving CR
Ara-C 60 mg m-2 s.c. b.d. given once in three blocks of 3,4
6TG 80 mg p.o. b.d. and 5 days respectively allowing
for neutrophil recovery between
each block.
Table I Outcome of induction chemotherapy
CR achieved
Without With
anthracycline anthracycline No CR Total
Age
median 28 35 33 30
range 6-56 15-39 15-52 6-56
Sex
male 20 4 4 28
female 15 6 3 24
FAB subtypes
0 1 3 4
1 1 1
2 10 1 1 12
3 1 3 1 5
4 10 3 2 15
5 7 3 10
6 4 4
7 1 1
Etoposide
o.d. 16 3 4 23
b.d. 19 7 3 29
Duration of
hospital stay
median 26 53 - 27
range 19-64 28-115 - 19-115
Total 35 10 7 52
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After neutrophil recovery, a bone marrow aspirate was
performed to assess response. If more than 10% blasts were
present, patients received Ara-C 10mgkg-' on days 1 and
10, 6TG 200mgm-2 on days 1, 2, 10, and 11, daunomycin
l.5mgkg-' on days 2 and 11, and adriamycin 1.5mgkg-'
on days 3 and 12. Adriamycin was used in conjunction with
daunorubicin because of its known efficacy in eliminating
solid tumour masses. It was anticipated that use of this drug
in patients with AML could expedite eradication of any
extramedullary disease, even if this was clinically undetect-
able.
Patients with 5-10% blasts after initial treatment were
discharged from hospital and received Ara-C 60 mg m-2 sub-
cutaneously, and 6TG 80 mg m-2 orally, given simultane-
ously twice daily for 5 days and repeated twice more at 5 day
intervals. If unacceptable pancytopenia was evident, further
therapy was delayed to permit neutrophil recovery to 0.5 x
1-9'1 .
Patients who did not achieve CR at this stage were con-
sider to have failed the protocol.
After achieving CR, all patients, except for those who had
received three 5-day blocks, received one further course of
low-dose Ara-C and 6TG (Figure 1). This was given in 3, 4
and 5 day blocks, allowing neutrophil recovery between each
block. Patients below 45 years of age with an HLA matched
sibling donor then received BMT. ABMT was offered to the
remaining medically fit patients during the last 3 years of the
study.
All patients received prednisolone eye drops every 2 h for
the first 10 days to reduce the incidence of conjunctivitis,
prophylactic anti-emetics, and loperamide or pethidine to
control diarrhoea. Granulocytopenic patients were nursed in
single rooms.
Conditioning for BMT and ABMT was melphalan 110 mg
m-2 followed by single dose total body irradiation (TBI) to a
midplane dose of 10 Gy (3 cGymin-') (Powles et al., 1980b).
BMT patients were nursed in protected environments. Oral
prophylactic antibiotics included neomycin, colistin, ampho-
tericin and nystatin. Patients developing fevers were treated
empirically with intravenous broad spectrum antibiotic com-
binations. Fungal infections, documented or suspected, were
treated with amphotericin. BMT patients received cyclo-
sporin as prophylaxis against graft versus host disease
(GVHD) (Powles et al., 1980b). Those developing GVHD
received high-dose methyl prednisolone (Kendra et al., 1981).
Marrow was not purged prior to ABMT, and patients receiv-
ed no subsequent maintenance chemotherapy.
Results
A total of 30 cases (58%) achieved CR with the first course
of treatment. A further five patients achieved CR (67%) with
further courses of 5-day Ara-C and 6TG, without use of an
anthracycline (Table I). Ten more (19%) with more than
10% blasts in their marrows after the first course of Ara-C
and etoposide, obtained CR after entering the treatment arm
containing adriamycin and daunomycin, giving an overall
CR rate of 86.5% (45/52). Following the first course of
treatment, the median interval to neutrophil recovery
(>0.5 x I0I1-) was 21 days (range 12 to > 100 days), and
to platelet recovery (> 100 x 109 l') was 21 days (range 14
to > 100 days). Median duration of hospitalisation was 27
days (range 19-115 days). It was longer for patients requir-
ing the anthracycline arm of the protocol (Table I). Suppor-
tive measures during remission induction included a median
of 11 units of blood, 45 units of platelets, 0.5 units of WBC
and 20 days of i.v. antibiotics (Table II).
Of 25 patients with a monocytic component to their
disease (FAB subtypes M4 and M5), 23 (92%) achieved CR,
17 (68%) without and six (24%) with an anthracycline. Seven
failed to achieve CR and thus failed the protocol (Table I).
Remission rates for patients receiving etoposide once daily
were identical to those receiving it twice daily (Table III).
The toxicity of Ara-C and etoposide is shown in Table IV.
Table II Supportive care during remission induction with BF II
Median no. Range
Days in hospital 27 (19-115)
Units of blood 11 (3-33)
Units ofplatelets 45 (9-144)
Units of WBC 0.5 (0-15) Days on i.v. antibiotics 20 (7-73)
Table III Results of CR-1 and etoposide schedule
Etoposide
Once daily Twice daily
(n = 23) (n = 29)
Achieved CR-I 20 (87%) 26 (89%)* Continued CR-I 12 (52%) 7 (24%)* Relapsed 5 (21%) 13 (45%)* afterchemotherapy alone 4 (17%) 9 (31%)* after ABMT 1 (4%) 4 (14%)* after BMT - -
*Not statistically significant.
Table IV Toxicity ofhigh dose Ara-C and etoposide
Etoposide
Total Once daily Twice daily
(n = 52) (n =23) (n = 29)
Diarrhoea 41 20 21
Abdominal pain 24 10 14
Vomiting 16 5 11
Intestinal obstruction 3 1 2
Meleana 2 1 1
Intestinal perforation I - I
Skin rash 11 6 5
Conjuctivitis 8 3 5
Fits/drowsiness 3 - 3
Treatment related mortality 5 3 2
Difference not statistically significant for any variable.
Major problems were gut-related. There was no statistical
difference, however, in toxicity between groups receiving etoposide one or twice daily. Treatment-related mortality was 9.4% (5/52).
Of the 45 remitters, 20 had no further remission induction
treatment, 14 received ABMT and 11 BMT while in CR 1 (Table V). Nineteen (42%) of these 45 patients continue in
first CR (7/11 with BMT; 6/14 with ABMT and 6/20 with no
treatment). Of the remaining 26, 17 relapsed (12/20 with no
treatment and 5/14 after ABMT), and nine died while in
remission (4/11 with BMT, 3/14 with ABMT and 2/20 with
no treatment). Five of the 17 who relapsed did so within 3
months of achieving CR. There was only one CNS relapse (FAB subtype M5) in the entire group.
With a minimum follow-up of 90 days, the actuarial
median duration ofdisease-free survival in CR1 was 321 days (range 13-911 days). Median duration of remission was shortest for the 29 patients who did not receive ABMT or BMT (180 days; range 13-782 days). This includes two
patients who died of fungal infection within the first month, while still in CR1 (Table IV). Median duration of remission
was 498 days (range 181-911) for ABMT and has not yet been achieved for BMT (range 118-906 days). The median interval from achieving CR to transplantation was 92 days for both autografts and allografts.
Quality of CR in patients receiving etoposide once daily is
compared to the twice daily group in Table IV. Of the patients continuing in CR1, 12/23 belonged to the former
and 7/29 to the latter group. Eleven of 17 (64%) who
relapsed achieved second CR (eight with chemotherapy, two with BMT in relapse and one with ABMT in relapse). Six of
these continue in second CR. Two of the four patients achieving CR2 with chemotherapy alone have subsequently
received an autograft using second remission marrow. Out-
come of the 5/11 patients not continuing in CR2 includes one in CR3 (after a second autograft in second relapse), one alive
in second relapse and three dead (two in second relapse and
one in CR2).
Currently, 26 (50%) ofpatients are in remission, 25 (48%)832 P. PARIKH et al.
Table V Status offirst CR
Chemotherapy Allogenic Autologous
alone BMT BMT Total
(n = 20) (n = 11) (n = 14) (n = 45)
Actuarial disease-free
survival in CR-I
median 180 a 498 321
range 13-782 118-906 181-911 13-911
Interval from CR to BMT
median - 92 92 92
range - 45-157 6-342 6-342
Current status
CCR 6 7 6 19
Died in CR 2 4 3 9
Relapsed
died with disease 4 - 2 6
achieved CR-2 8b 3 11
aNotyetachieved.bCR-2achievedwithchemotherapyinfive, BMTintwoandABMTin
one of these patients.
are dead and one (2%) is alive with disease. Of the 25 who
died, 11 had active disease, nine died of transplant-related
causes (five infection, three GVHD, one progressive quadra-
paresis) and five had induction protocol toxicity (three infec-
tions, two gut toxicity).
A multivariant regression analysis was undertaken, in
which age at presentation, sex, WBC count at diagnosis,
blast percentage at presentation, FAB subtype and time to
platelet and polymorph recovery after chemotherapy were
considered as dependent variables. None showed any statis-
tical significance with respect to achieving or remaining in
CR.
Discussion
Management ofAML remains problematic because of failure
to improve cure rates (Hurd, 1987; Powles et al., 1980a;
Mayer, 1987; Preisler et al., 1987a; Cassileth et al., 1987;
Rohatiner et al., 1988). This is partly attributable to lack of
matched sibling donors for many patients, increased drug
toxicity in the elderly, and a high incidence of relapse partic-
ularly in FAB subtypes with a monocytic component (Hurd,
1987; Mayer et al., 1987; Peterson et al., 1987).
Standard protocols containing Ara-C and daunorubicin
with or without 6 thioguanine have recently been reported to
give CR rates of 57-72% in de novo AML (Hurd, 1987;
Preisler et al., 1987a; Cassileth et al., 1987; Capizzi et al.,
1987; Reiffers et al., 1989). We obtained a CR rate of 67%
without use of an anthracycline, and an overall CR rate of
86.5% where an anthracycline was used in ten (19%)
patients. Remission was obtained in a single admission.
Median duration of hospitalisation was shorter than for
patients receiving the 3 plus 10 DAT regimen in the MRC 9
trial (Rees, 1989), and contrasts with previous reports which
failed to demonstrate any benefit from addition of other
chemotherapeutic agents to high-dose Ara-C alone for newly
diagnosed AML (Gale et al., 1987).
Low-dose Ara-C and 6TG maintained patients in remis-
sion during evaluation for BMT. As expected, median dura-
tion of first CR was shortest in patients receiving no further
treatment after obtaining CR (Reiffers et al., 1989). Of the 11
patients in first CR receiving allogeneic BMT, seven continue
to be event-free survivors with a probability of surviving in
continued CR of 62.3% at 18 months. No patient receiving
BMT in CR1 has relapsed. There have been no adverse
events after 10 months, and five patients are well up to 36
months from allograft.
Of the 19 patients who continue in first CR, 15 (80%) did
not require an anthracycline. The proportion of patients
continuing in first CR without an anthracycline (15/35; 43%)
parallels that which did require an anthracycline (4/10; 40%).
This would imply that efficiency of Ara-C and etoposide in
inducing long-term DFS may be comparable to that achieved
using an anthracycline-containing regimen (Mayer, 1987;
Preisler et al., 1987b; Cassileth et al., 1987; Capizzi et al.,
1987). Patients receiving etoposide once daily fared better
(52% CCR) than those receiving it twice daily (24% CCR)
even though the initial CR rate was comparable (87% and
98%) respectively. Twice daily administration failed to pro-
long CR and caused an unacceptably high incidence of gut
toxicity.
There was no evidence that any specific subgroup ofAML
fared worse with respect to disease characteristics at presen-
tation. Specifically, patients with a monocytic component to
their disease (FAB subtypes M4 and M5) did as well as
others. Only one patient sustained a CNS relapse. Although
not statistically significant, there is some indication that
patients with M3 morphology fare better with inclusion of an
anthracycline (Table I).
Treatment-related mortality during induction was less than
10% (5/52), and includes three infective deaths and two from
gut toxicity. This is comparable to other protocols using
high-dose Ara-C (Capizzi et al., 1987; Gale et al., 1987). No
patient receiving etoposide once daily developed CNS tox-
icity. In general, toxicity was considerably less than pre-
viously reported in patients with relapsed and refractory
acute leukaemias (Gore et al., 1989). In the group as a whole,
the majority of deaths were due to disease (Morra et al.,
1984), seven failing to remit and the remainder relapsing.
Twice daily administration of etoposide failed to produce an
improved anti-leukaemia effect.
We conclude that this protocol constitutes a safe, fast and
effective induction regimen for de novo AML. Patients remit-
ting after the first course of chemotherapy were discharged
from hospital as rapidly as after 21 days, consolidation
therapy being administered on an outpatient basis. Subse-
quent bone marrow transplantation was not compromised,
results being comparable to those published using alternative
induction regimens such as DAT (Helenglass et al., 1987).
Results for the group who received BMT in CR1 are com-
parable to those seen in the MRC AML9 trial (personal
communication, J.H. Rees).
Patients require long-term evaluation, but there is sufficient
evidence to warrant further studies designed to ascertain
optimal dosages to maximise chances of cure.
With recent emphasis on medical audit, it can be said that
BFl1 patients are in hospital for a shorter time than those
treated in the MRC AML 9 DAT trial, and that they require
less support and experience superior remission induction
rates with a lower relapse probability.
Cost of BMT has not been considered here and requires
evaluation, although BMT procedures are generally applic-
able in acute myeloid leukaemia, regardless of the chemo-
therapy induction regimen used to effect remission.
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